Skip to main content

Issue Navigation

Vol. 11, No. 02 March 2013

 

Groundbreaking AIDS research presented at the 20th Conference on Retroviruses and Opportunistic Infections, such as the toddler case covered in this issue of VAX, could be hurt by the across-the-board US spending cuts that took effect March 1 (see IAVI Report blog). With the US National Institutes of Health in danger of losing US$1.5 billion of its $31 billion budget, volunteers from more than 100 organizations rallied April 8 in Washington, D.C. to protect funding for biomedical research. Visit the IAVI Report blog for live coverage of the event.












A Functionally Cured
CROI Baby?

March meeting showcases new data on PrEP, hormonal contraception and vaccines—but a toddler steals the show

The 20th Conference on Retroviruses and Opportunistic Infections (CROI) opened in Atlanta with a blockbuster about a Mississippi toddler who appears to be the first child—and only the second person—to have been functionally cured of HIV. The toddler was abruptly taken off treatment after receiving antiviral drugs during the first 18 months of life. Several months later, doctors could find no detectable replication-competent virus in the toddler’s blood or any evidence of disease.

Unveiled at an early press conference and rounded out a day later in an oral abstract session, the case report sparked a rare media firestorm for the organizers of this otherwise low-key, science-heavy meeting. Within 72 hours, a news story by The Associated Press had generated close to 5,000 comments on The Huffington Post website. The story captivated the blogosphere for days. READ MORE »

SPECIAL FEATURE


Curtains Down for the NEPRC

The planned closure of the New England Primate Research Center shocks and dismays many in the close-knit community of HIV researchers who conduct primate studies. READ MORE »

BLOG POSTS


Large AIDS vaccine trial shudders to a halt

A large Phase IIb trial testing the safety and efficacy of a DNA/Ad5 prime-boost regimen of two vaccine candidates developed by the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases has discontinued immunizations. READ MORE »


HVTN 505: "A hard blow"

It’s probably a bit of an understatement to say vaccine researchers were disappointed yesterday, when they heard about the discontinuation of HVTN 505, a clinical trial that tested the efficacy of a DNA/Ad5 prime-boost vaccine regimen in about 2,500 people. When the trial was stopped, there was no significant difference in HIV infections between those who received the candidate vaccines and the placebo recipients. Beyond that, there was a—statistically insignificant—trend towards more infections among the vaccinated. READ MORE »

Learn the Basics

image description

Understanding Therapeutic Vaccination

What is therapeutic vaccination and how are scientists using it today to develop new strategies against HIV?

READ MORE

Clinical Trials Database

image description

Explore

An interactive search of trials and results

READ MORE

IAVI REPORT

The Journal of AIDS Vaccine Research A Toddler Stole the Show

The report of a child functionally cured of HIV stirred up the typically staid proceedings of the Conference on Retroviruses and Opportunistic Infections.

Subscribe